Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Inhibition of fibronectin deposition improves experimental liver fibrosis.

Altrock E, Sens C, Wuerfel C, Vasel M, Kawelke N, Dooley S, Sottile J, Nakchbandi IA.

J Hepatol. 2015 Mar;62(3):625-33. doi: 10.1016/j.jhep.2014.06.010. Epub 2014 Jun 16. Erratum in: J Hepatol. 2015 Jun;62(6):1455-6.

PMID:
24946284
2.

Fibronectin protects from excessive liver fibrosis by modulating the availability of and responsiveness of stellate cells to active TGF-β.

Kawelke N, Vasel M, Sens C, Au Av, Dooley S, Nakchbandi IA.

PLoS One. 2011;6(11):e28181. doi: 10.1371/journal.pone.0028181. Epub 2011 Nov 28.

3.

Kindlin-3-mediated signaling from multiple integrin classes is required for osteoclast-mediated bone resorption.

Schmidt S, Nakchbandi I, Ruppert R, Kawelke N, Hess MW, Pfaller K, Jurdic P, Fässler R, Moser M.

J Cell Biol. 2011 Mar 7;192(5):883-97. doi: 10.1083/jcb.201007141. Epub 2011 Feb 28.

4.

Circulating fibronectin affects bone matrix, whereas osteoblast fibronectin modulates osteoblast function.

Bentmann A, Kawelke N, Moss D, Zentgraf H, Bala Y, Berger I, Gasser JA, Nakchbandi IA.

J Bone Miner Res. 2010 Apr;25(4):706-15. doi: 10.1359/jbmr.091011.

5.

Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation.

Kawelke N, Bentmann A, Hackl N, Hager HD, Feick P, Geursen A, Singer MV, Nakchbandi IA.

J Bone Miner Res. 2008 Aug;23(8):1278-86. doi: 10.1359/jbmr.080313.

Supplemental Content

Loading ...
Support Center